Followers | 601 |
Posts | 29852 |
Boards Moderated | 0 |
Alias Born | 01/30/2012 |
Friday, August 04, 2023 6:18:04 PM
The existing tests take at least 5 days. This test comes back with the results in 3-5 hours. Also using this test they don’t need to separate out anything like plasma or anything. All they need is 4ml of whole blood - meaning what comes out of your arm into the needle then into the test tube and only 4ml of it.
There’s approximately 350,000 Sepsis infections in the USA alone every year.
The US Government will subsidise the cost of the test for the first $97.50.
Also, the test already has the CE mark so it’s approved for use in the European Union. So that’s a population of 350m. Then the USA population is at least 320m last time I checked.
One debt holder has swapped $10m worth of debt for equity in the company and there’s a guy on StockTwits who between himself and the largest institutional investor has loaded up on another 10m shares today according to his posts.
Then they have a strong pipeline of other products as well.
But here’s the thing. Just remember this is a diagnostic test getting approved. It’s not a drug going through Phase I trials etc etc.
Just think about it. The FDA wouldn’t ever fast track anything unless it was already quite likely to get approved.
This is a blood test. All they need to do is prove it works with independent data to get the approval.
Well worth taking a look at the company website.
Also (almost forgot) the CEO is a survivor of a Sepsis infection himself and that is why he sought out the company. It took several days for his infection to be diagnosed and the correct treatment started for the antibiotic resistant infection that he had.
My post are my opinion only. You should do your own due diligence before investing in any stock or take professional advice. I am not an investment advisor. Kind Regards.
Recent TTOO News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/21/2025 10:19:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2025 02:23:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/08/2025 10:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2025 02:05:31 PM
- T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 01/07/2025 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 11:55:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 11:46:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 11:20:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 11:18:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 11:16:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 11:13:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 11:07:27 PM
- T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor • GlobeNewswire Inc. • 12/18/2024 02:00:00 PM
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally • GlobeNewswire Inc. • 12/17/2024 02:00:00 PM
- T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. • GlobeNewswire Inc. • 12/16/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2024 02:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/09/2024 02:02:59 PM
- T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens • GlobeNewswire Inc. • 12/09/2024 02:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/20/2024 09:45:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/20/2024 09:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2024 02:54:00 PM
- T2 Biosystems Announces Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 11/14/2024 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 08:49:19 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/14/2024 08:38:45 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/08/2024 10:00:29 PM
UC Asset Announces Plan of Secondary Public Offering via Reg A • UCASU • Jan 23, 2025 9:30 AM
Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • ZEFIF • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM